Success Metrics

Clinical Success Rate
85.7%

Based on 18 completed trials

Completion Rate
86%(18/21)
Active Trials
23(35%)
Results Posted
22%(4 trials)
Terminated
3(5%)

Phase Distribution

Ph not_applicable
21
32%
Ph early_phase_1
14
22%
Ph phase_3
1
2%
Ph phase_4
3
5%
Ph phase_2
11
17%
Ph phase_1
8
12%

Phase Distribution

22

Early Stage

11

Mid Stage

4

Late Stage

Phase Distribution58 total trials
Early Phase 1First-in-human
14(24.1%)
Phase 1Safety & dosage
8(13.8%)
Phase 2Efficacy & side effects
11(19.0%)
Phase 3Large-scale testing
1(1.7%)
Phase 4Post-market surveillance
3(5.2%)
N/ANon-phased studies
21(36.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

18 of 22 finished

Non-Completion Rate

18.2%

4 ended early

Currently Active

23

trials recruiting

Total Trials

65

all time

Status Distribution
Active(31)
Completed(18)
Terminated(4)
Other(12)

Detailed Status

Completed18
Recruiting17
unknown12
Active, not recruiting6
Not yet recruiting4
Enrolling by invitation4

Development Timeline

Analytics

Development Status

Total Trials
65
Active
23
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 114 (24.1%)
Phase 18 (13.8%)
Phase 211 (19.0%)
Phase 31 (1.7%)
Phase 43 (5.2%)
N/A21 (36.2%)

Trials by Status

completed1828%
active_not_recruiting69%
recruiting1726%
terminated35%
unknown1218%
not_yet_recruiting46%
withdrawn12%
enrolling_by_invitation46%

Recent Activity

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT06503146Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Recruiting
NCT07285993Phase 2

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Not Yet Recruiting
NCT07553741Not Applicable

Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Completed
NCT03181867Phase 2

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Active Not Recruiting
NCT03173924Phase 2

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Active Not Recruiting
NCT05876858Early Phase 1

EXPLORER Total Body PET/CT Imaging for Myofascial Pain

Active Not Recruiting
NCT06014515Early Phase 1

Single-tracer Multiparametric PET Imaging

Recruiting
NCT05321316Not Applicable

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Recruiting
NCT05436093Not Applicable

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Recruiting
NCT04016818Early Phase 1

Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution

Not Yet Recruiting
NCT04273555Phase 1

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Withdrawn
NCT04459273Phase 1

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Active Not Recruiting
NCT05641753Phase 4

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Recruiting
NCT04457258Early Phase 1

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Active Not Recruiting
NCT04147494Early Phase 1

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Active Not Recruiting
NCT06383598Not Applicable

PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors

Recruiting
NCT07023861Early Phase 1

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

Enrolling By Invitation
NCT07023848Early Phase 1

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

Enrolling By Invitation
NCT06453915Early Phase 1

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Recruiting
NCT06717113Early Phase 1

A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
65